Systematic review on poly ADP ribose polymerase inhibitors for treating recurrent ovarian cancer / 重庆医学

ABSTRACT

Objective To evaluate the efficacy and safety of poly ADP ribose polymerase (PARP) inhibitors for treating recurrent ovarian cancer.Methods The databases of Medline,Embase,Central and SinoMed were retrieved with the retrieval time from their establishment to September 2017;in addition the related reference literatures were manually retrieved.The randomized controlled trials (RCTs) of PARP inhibitors for treating recurrent ovarian cancer were included.The meta analysis was performed by using the RevMan 5.3 software.Results A total of 5 RCTs were included,including 1 160 cases in the experimental group and 679 cases in the control group.When compared with placebo,PARP inhibitors significantly improved the progression-free survival [HR=0.34,95％CI(0.30,0.40),P＜0.01] and overall survival [HR=0.73,95％CI(0.55,0.96),P=0.025],and increased objective response rate [RR=2.56,95％CI(1.17,5.59),P=0.020].The addition of PARP inhibitors to chemotherapy reduced the risk of disease progression [HR =0.51,95 ％CI (0.34,0.77),P =0.001].However,there were no statistically significant differences in overall survival [HR=1.17,95％CI(0.79,1.73),P=0.440] and objective response rate [RR=1.11,95％CI(0.86,1.42),P =0.420] between the PARP inhibitors plus chemotherapy group and the chemotherapy alone group.The administration of PARP inhibitors was associated with a significantly increased risk of serious anemia,fatigue,nausea and vomiting.Conclusion PARP inhibitors could improve the progression-free survival outcome in recurrent ovarian cancer.